Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 18, 2003. The report details specific corporate actions regarding share buybacks and changes in directors' interests in the company's ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share repurchase transactions:
- December 16, 2003: Purchased 1,150,000 shares for cancellation at 1,272.7 pence per share.
- December 17, 2003: Purchased 1,150,000 shares for cancellation at 1,269.43 pence per share.
Material Changes
The primary material changes reported are the reduction of the company's share capital through the cancellation of 2,300,000 ordinary shares over two consecutive days. Additionally, the GlaxoSmithKline Employee Trust transferred shares to participants in the SmithKline Beecham Employee Share Option Plan 1991:
- 47,594 shares transferred on December 15, 2003.
- 23,948 shares transferred on December 16, 2003.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. The share repurchases were executed in accordance with authority granted by shareholders at the Annual General Meeting on May 19, 2003.
Key Facts for Investor Verification
- Verify the total number of shares repurchased and cancelled (2,300,000) against the company's authorized buyback limit from the May 2003 AGM.
- Confirm the average price paid per share (approximately 1,271 pence) relative to the market price on those dates.
- Review the impact of the share cancellations on the company's total outstanding share count and earnings per share.
- Note that the filing does not contain quarterly or annual financial performance data.